TriangleARCHER (NCT05950139)
ARCHER trial for NSCLC Stage IV (NCT05950139). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
For lung cancer driven by an ALK gene fusion, targeted pills work well, sometimes for years. Then resistance arrives; it almost always does.
The idea: vaccinate while the drug is still working, so the immune system learns the tumor before it changes.
The ALK fusion protein exists only in cancer cells, which makes it a clean target. At Johns Hopkins, patients whose disease is stable on an ALK inhibitor receive a peptide vaccine, fragments of the ALK protein with an immune adjuvant, to raise T cells against any cell carrying it. So when drug-resistant cells emerge, the immune system is already watching.
ARCHER is a small early safety study; the drug continues throughout. Vincent Lam leads it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.